2. UroToday Home
  3. Video Lectures

ASCO GU 2023 Videos

Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
Insights into Global Treatment Patterns for Advanced Prostate Cancer: The IRONMAN Registry - Lorelei Mucci &. Dan George
Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky
Neoadjuvant Chemo-Immunotherapy Affect on Downstaging in Cisplatin-Eligible and Ineligible MIBC Patients Prior to Definitive Surgery, HCRN GU14-188: Phase Ib/II Study - Jason Brown
Analyzing the Impact of Residual Disease Treatment on Complete Response Rate in Metastatic Renal Cell Carcinoma - Fabien Moinard-Butot
Challenges, Controversies, and Opportunities of PARP Inhibitor Combinations with Androgen Receptor Signaling Inhibitors - Kim Chi
Interim Overall Survival Analysis of TRITON3: Rucaparib vs Physician's Choice of Therapy in mCRPC with Homologous Recombination Deficiency - Alan Bryce
Exploring the Latest Advances in Advanced Prostate Cancer Treatment - Oliver Sartor
Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew Galsky
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset - Tanya Jindal & Vadim Koshkin
Assessing the Impact of Enfortumab Vedotin and Pembrolizumab on QoL and Symptom Management in Urothelial Carcinoma: EV-103 Cohort K Study Results - Matthew Milowsky
Effect of Cerebral Dopamine Metabolism Genetic Polymorphism on Patient-Reported Quality of Life in mHSPC - Arjun Gupta & Alicia Morgans
NCI-FDA Unit Aims to Streamline Drug Development for Cancer Patients - Michael Morris
Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial - Michiel Van der Heijden
The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky
Neoadjuvant Versus Adjuvant Chemotherapy in Patients With Clinically Node-positive UTUC Who Underwent a Radical Nephroureterectomy - Karan Jatwani
The Role of Adjuvant Chemotherapy, Versus Observation, in Patients With Upper Urinary Tracts With Variant Histology Undergoing a Radical Nephroureterectomy - Karan Jatwani
Advances in Advanced Prostate Cancer - Silke Gillessen
Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar
Testosterone Recovery in Patients With Prostate Cancer Treated With Radiotherapy Plus ADT - Tanya Dorff
Brain Metastases From Renal Cell Carcinoma Treated With First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium - Kosuke Takemura
Overall Survival and Efficacy Results of Second-line Treatment for Patients With Metastatic Clear Cell Renal Cell Carcinoma, BIONIKK Trial -Yann Vano
Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center - Thomas Hope
A Novel Patient-reported Outcome Measure for Patients With Prostate Cancer Receiving Radionuclide Therapy: FACT-RNT - Lisa Gudenkauf
Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA - Jones Nauseef
An Integrative Platform of Whole Genome and Transcriptome Sequencing to Identify Additional Targets in Advanced Prostate Cancer - Jones Nauseef
3-Year Follow-up CheckMate 9ER Trial: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma - Mauricio Burotto
CaboPoint Study: Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma - Laurence Albiges
Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Extended Follow-up Results of Cohort 10 of the COSMIC-021 Study - Bradley McGregor
BXCL701 Combined with Pembrolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype - Rahul Aggarwal
Novel Antiandrogens Added to ADT Improves Outcomes in a Subset of High Risk Prostate Cancer Patients - Paul Ngueyn
Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi
Results from Cohort B of the Phase 2 KEYNOTE-057 Trial, Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to BCG - Andrea Necchi
The Evolving Field of Kidney Cancer Treatment: The COSMIC-313 Trial and Beyond - Thomas Powles
Improving Genetic Testing Rates in Advanced Prostate Cancer - Pedro Barata
Neoadjuvant Nivolumab and Ipilimumab for Upper Tract Urothelial Cancer - Min Yuen Teo
A SEER-Medicare Based Quality Score for Patients with Both Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma - Daniel Joyce
Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi
Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
Delaying Time to Metastasis in Patients With High-Risk, M0 CRPC With Radiolabeled J591 Plus Ketoconazole and Hydrocortisone - Scott Tagawa
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar
Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer- Andrew Laccetti
Oral EPI-7386 Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer - Russell Pachynski
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
The SunRISe-4 Trial: A Critical Look at Immunotherapy in Bladder Cancer - Sarah Psutka
The Benefit of the Addition of Talazoparib to Enzalutamide in First Line Treatment for mCRPC TALAPRO-2 - Neeraj Agarwal
Exploring Prostate Cancer Data from GU ASCO 2023: Triplet Therapy and PARP Inhibitors in Focus - Cora Sternberg
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer - Elena Castro
Phase 3 ARASENS Study, The Impact of Disease Burden and Risk on Efficacy and Safety Outcomes - Matthew Smith
The Role of Neoadjuvant Chemotherapy on Pathological Stage and Survival in Sarcomatoid Bladder Cancer – Arya Roy
Reduction in the Risk of Recurrence with the Use of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer In An Equal Access Setting - Stephen Williams
Treating Biochemical Recurrence With Enhanced Therapy Added to Standard of Care and Targeted Radiation Using PET Imaging, ECOG-ACRIN EA8191 (INDICATE) - Neha Vapiwala
Results from the Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma (ZIRCON) - Brian Shuch
TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy - Petros Grivas
The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo
HCRN GU 16-260, Nivolumab and Salvage Nivolumab+Ipilimumab in Patients with Advanced Renal Cell Carcinoma Cohort A, Treatment-Free Survival Outcomes - Michael Atkins
Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose